What are the potential harms of PSA screening, and how can I decide if it’s right for me?

PSA testing can lead to false‑positive results, prompting unnecessary biopsies that carry risks such as infection or bleeding. Overdiagnosis may also result in treatment for cancers that would never become life‑threatening. Discuss your personal risk factors, life expectancy, and preferences with your doctor to weigh benefits versus harms.

At what age should I begin routine PSA screening, and how often should I get tested?

Most guidelines recommend starting discussions about PSA screening at age 45 for men at average risk and at age 40 for those with a family history of prostate cancer or African‑American ancestry. Once screening begins, PSA testing is typically repeated every 1–2 years, but the interval can be adjusted based on prior results and overall health.

If my PSA level is slightly above the normal range, what steps should I take next?

single elevated PSA is not diagnostic. Your doctor may repeat the test after a few weeks, perform a digital rectal exam (DRE), and possibly order a prostate MRI or transrectal ultrasound to better assess the gland. If imaging suggests a suspicious area, a targeted biopsy may be recommended.

How does a digital rectal exam complement PSA testing in prostate cancer screening?

DRE allows the clinician to feel for lumps, nodules, or asymmetry in the prostate that PSA alone cannot detect. While PSA measures a protein level in the blood, DRE provides direct physical assessment. Together, they improve the likelihood of detecting clinically significant cancers, especially when PSA levels are borderline.===

Prostate Cancer Screening

Prostate cancer screening involves tests to detect signs of cancer before symptoms appear, aiming to identify aggressive cases early while balancing the potential risks of over-diagnosis and treatment.

Overview

Cancer is a disease characterized by uncontrolled cell growth. Screening involves undergoing tests to look for signs of cancer before any symptoms are present. By the time cancer causes symptoms, it may have already spread to other parts of the body. A screening test may help find cancer early, when it may be easier to treat.

It is important to note that cancer screening only indicates whether you might have cancer; it does not diagnose cancer. If a screening test shows signs of cancer, additional tests are required to determine if cancer is present and how serious it may be.

What is Prostate Cancer?

Prostate cancer screening looks for signs of cancer in the prostate, a gland in the male reproductive system located just below the bladder. The prostate produces fluid that is part of semen.

Prostate cancer is most common in people over age 50. It usually grows slowly and often does not cause health problems. It is possible to live a long life with prostate cancer without ever knowing you have it. However, in certain cases, prostate cancer may spread to other parts of the body and become very serious. The goal of screening is to find prostate cancers that are more likely to spread so they can be treated early.

Screening Tests

Two tests are commonly used to screen for prostate cancer:

Prostate-Specific Antigen (PSA) Blood Test: PSA is a protein made by the prostate. A high level of PSA in the blood may indicate prostate cancer, but it is not proof of cancer. Many other factors can cause high PSA levels, including:
- Having an enlarged prostate (benign prostatic hyperplasia or BPH)
- Having other common prostate problems
- Taking certain medicines
In general, the higher the PSA level, the more likely it is that cancer is present. However, a low PSA blood level is not a guarantee that cancer is absent.
Digital Rectal Examination (DRE): This is a physical prostate exam where a health care provider inserts a lubricated, gloved finger into the rectum to feel the prostate for lumps or anything unusual. A DRE can check only one side of the prostate.

While a PSA test or a DRE may detect prostate cancer at an early stage, it is not clear whether early detection and treatment lower the risk of dying from prostate cancer. Patients should discuss the benefits and harms of screening with their provider.

Benefits and Harms

Possible Benefits

Finding and treating prostate cancer early before it spreads.
Gaining a better sense of prostate cancer risk based on PSA test results.
Experiencing peace of mind if screening shows a low likelihood of having prostate cancer.
Having the option to choose further testing and closely monitor the prostate if screening suggests cancer may be present.

Possible Harms

False Positive Results: A PSA test may show signs of prostate cancer when none is actually present. This can lead to:
- Worry while undergoing additional tests to look for signs of cancer.
- A prostate biopsy, where a doctor removes tissue from the prostate to study under a microscope for cancer cells. This is the only way to diagnose cancer. Possible harms of a biopsy include:
  - Fever
  - Pain
  - Blood in semen
  - Urinary tract infection
Unnecessary Treatment: Screening may lead to a cancer diagnosis, but it is not always clear whether the cancer is likely to grow and spread. This can result in unnecessary treatment for cancer that would never have caused health problems. Common prostate cancer treatments may have serious, permanent complications, such as:
- Urinary incontinence
- Erectile dysfunction
- Problems controlling bowel movements

Who Should Be Screened?

Because there are both benefits and risks to prostate screening, patients should talk with their provider to decide if screening is appropriate. The decision should consider the following factors:

Age: The risk of prostate cancer increases after age 50.
Family Health History: If family members have had prostate cancer, the risk may be higher.
Race: Prostate cancer is more common in African Americans, who also have a higher risk of developing it at a younger age and having more serious disease.
General Health: Whether the patient is well enough to undergo treatment if prostate cancer is found.
Personal Preferences: How the patient feels about the possible benefits and harms of screening, diagnosis, and treatment.